CTOs on the Move

Trevi Therapeutics

www.trevitherapeutics.com

 
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Trevi Therapeutics raised $50.5M on 07/20/2017
Trevi Therapeutics raised $55M on 04/07/2022

Similar Companies

Envision Wellness

Envision Wellness WNY Behavioral Health has been providing counseling and treatment services in WNY for decades to all persons who have requested guidance.

StemCapture

StemCapture is a Pittsford, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ajinomoto AminoScience

Ajinomoto AminoScience is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mission Cancer + Blood

As you or a loved one fight the unimaginable, we are right by your side, and right next door. Mission is a community-based healthcare team...

Occlutech

Occlutech was founded in Germany in 2003, and has since developed into one of the world´s leading suppliers in the area of structural heart disease with products and projects for; congenital defects, stroke prevention, and heart failure.